Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)

Monomethyl auristatin E (MMAE) is one of the most commonly used payloads for developing antibody–drug conjugates (ADC). However, limited studies have comprehensively evaluated the whole-body disposition of MMAE. Consequently, here, we have investigated the whole-body pharmacokinetics (PK) of MMAE in...

Full description

Bibliographic Details
Main Authors:	Hsuan Ping Chang, Yuen Kiu Cheung, Dhaval K. Shah
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Journal of Clinical Medicine
Subjects:	antibody–drug conjugate (ADC) monomethyl auristatin E (MMAE) biodistribution tissue pharmacokinetics (PK) physiological-based pharmacokinetic (PBPK) model
Online Access:	https://www.mdpi.com/2077-0383/10/6/1332

Similar Items

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
by: Hsuan-Ping Chang, et al.
Published: (2023-04-01)

Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
by: Hanhee Cho, et al.
Published: (2022-10-01)

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
by: Anna M. Serwotka-Suszczak, et al.
Published: (2017-02-01)

Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility
by: Tero Satomaa, et al.
Published: (2018-03-01)

Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines
by: Ariana Abawi, et al.
Published: (2021-04-01)

Monomethyl auristatin E Exhibits Potent Cytotoxic Activity against Human Cancer Cell Lines SKBR3 and HEK293
by: Meghdad Abdollahpour-Alitappeh, et al.
Published: (2017-10-01)

Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
by: Min-Ho Park, et al.
Published: (2019-07-01)

Monomethyl Auristatin E, a Potent Cytotoxic Payload for Development of Antibody-Drug Conjugates against Breast Cancer
by: Meghdad Abdollahpour-alitappeh, et al.
Published: (2017-06-01)

Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY<sup>®</sup>) Antibody–Drug Conjugate in Sprague Dawley Rats
by: Victor Yip, et al.
Published: (2021-03-01)

Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies
by: Chunze Li, et al.
Published: (2020-01-01)

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
by: Peggy Liu-Kreyche, et al.
Published: (2019-07-01)

Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy
by: Yanming Wang, et al.
Published: (2019-07-01)

Physiologically Based Pharmacokinetics Model in Pregnancy: A Regulatory Perspective on Model Evaluation
by: Paola Coppola, et al.
Published: (2021-06-01)

Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution
by: Hinojal Zazo, et al.
Published: (2022-02-01)

An integrated exposure and pharmacokinetic modeling framework for assessing population-scale risks of phthalates and their substitutes
by: Yaoxing Wu, et al.
Published: (2021-11-01)

Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population
by: Andrew Lim, et al.
Published: (2023-05-01)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
by: Sumit Basu, et al.
Published: (2020-06-01)

Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer
by: Xinning Wang, et al.
Published: (2021-01-01)

Review of the pharmacokinetics of nanodrugs
by: Shao Xiaotong, et al.
Published: (2023-03-01)

Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human
by: Fen Yang, et al.
Published: (2017-10-01)

Development of a multi-route physiologically based pharmacokinetic (PBPK) model for nanomaterials: a comparison between a traditional versus a new route-specific approach using gold nanoparticles in rats
by: Wei-Chun Chou, et al.
Published: (2022-07-01)

A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs
by: Aman P. Singh, et al.
Published: (2019-02-01)

Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics
by: Xinxin Yang, et al.
Published: (2023-12-01)

Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling
by: Ruifang Guan, et al.
Published: (2023-11-01)

Physiologically Based Pharmacokinetic Modelling and Simulation to Predict the Plasma Concentration Profile of Doxorubicin
by: George A. Mystridis, et al.
Published: (2022-02-01)

Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
by: Yanming Wang, et al.
Published: (2020-03-01)

Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling
by: Seung-Hyun Jeong, et al.
Published: (2022-12-01)

Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation
by: Mohamed Aborig, et al.
Published: (2019-04-01)

Optimizing the enzymatic release of MMAE from isoDGR-based small molecule drug conjugate by incorporation of a GPLG-PABC enzymatically cleavable linker
by: Marco Zambra, et al.
Published: (2023-07-01)

Unravelling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
by: Xiaoxia eYang, et al.
Published: (2015-01-01)

Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling
by: Pieter-Jan De Sutter, et al.
Published: (2023-09-01)

Investigation of pharmacokinetics and immunogenicity of magnetosomes
by: M. Haripriyaa, et al.
Published: (2024-12-01)

A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia
by: Samia Kalsoom, et al.
Published: (2024-02-01)

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
by: Efrat T. Harel, et al.
Published: (2019-11-01)

Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability
by: Zaril H. Zakaria, et al.
Published: (2018-07-01)

Quantification of a Novel Photosensitizer of Chlorin e6-C15-Monomethyl Ester in Beagle Dog Plasma Using HPLC: Application to Pharmacokinetic Studies
by: Xiuxiu Li, et al.
Published: (2017-04-01)

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population—Current Advances, Challenges, and Opportunities
by: Jean Dinh, et al.
Published: (2023-11-01)

MMAE-loaded PLGA nanomedicine with improved biosafety to achieve efficient antitumor treatment
by: Changqiang Xie, et al.
Published: (2024-03-01)

Bivalent EGFR-Targeting DARPin-MMAE Conjugates
by: Lennard Karsten, et al.
Published: (2022-02-01)

A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution
by: Radwan Ansaar, et al.
Published: (2023-04-01)